Navigation Links
Smallpox Vaccine Clinical Study Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting Healthy M/F Age 18-40
Date:3/27/2013

Orlando, Florida (PRWEB) March 27, 2013

*Avail Clinical Research conducts Clinical Trials near Orlando, FL. For more information about participating in this Vaccine Clinical Trial, please visit our website or contact us directly at (386) 310-1334

BACKGROUND & SCIENTIFIC RATIONALE

Despite the fact that the World Health Organization (WHO) officially declared successful global eradication of smallpox in 1980, the existence of variola stockpiles and the threat of bioterrorism demands to maintain immunity to smallpox through vaccination.

After the events of September 11th, 2001, concern over the use of bioweapons as agents of terrorism increased. As mass vaccination programs halted more than 30 years ago, it is estimated that the majority of the world population has no existing immunity to smallpox, and as such, the release of this highly contagious virus would have devastating effects.

As a consequence, there is an urgent need for a safe and efficacious vaccine to protect the public against smallpox.

PRIMARY OBJECTIVE

-To assess the consistency of three consecutively produced IMVAMUNE® lots.

SECONDARY OBJECTIVE

-To assess uncommon adverse reactions, in particular any cardiac sign and symptom indicating a case of myo-/pericarditis, and to compare the frequency of those reactions against placebo.

-To collect vaccinia-specific humoral immune response data.

INCLUSION CRITERIA

1. Male and female subjects, 18 to 40 years of age

2. The subject has read, signed and dated the informed consent form, having been advised of the risks and benefits of the trial in a language understood by the subject and prior to performance of any trial specific procedures

3. BMI greater than/equal to 18.5 and less than 35

4. Women of childbearing potential (WOCBP) must have used an acceptable method of contraception for 30 days prior to the first vaccination, must agree to use an acceptable method of contraception during the trial, and must avoid becoming pregnant for at least 28 days after the last vaccination. A woman is considered of childbearing potential unless post-menopausal or with a history of hysterectomy (Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products)

5. WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to each vaccination

6. White blood cells greater than/equal to 2,500/mm3 and less than ULN

7. Absolute neutrophil count (ANC) within normal limits

8. Hemoglobin within normal limits

9. Platelets within normal limits

10. Adequate renal function defined as a calculated Creatinine Clearance (CrCl) greater than 60 ml/min as estimated by the Cockcroft- Gault equation

11. Adequate hepatic function

12. Troponin I less than 2 x ULN

13. Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of atrioventricular or intraventricular conditions or blocks such as complete left or right bundle branch block, AV node block, QTc or PR prolongation, premature atrial contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two premature ventricular contractions in a row, ST elevation consistent with ischemia)

For information about how to participate in a Vaccine Clinical Trial, visit Avail Clinical Research or contact us directly at (386) 310-1334

Read the full story at http://www.prweb.com/releases/trials/smallpox/prweb10567096.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Man Who Got Smallpox Vaccine Passes Milder Infection to Sex Partner: CDC
2. Study: Research reveals protective properties of influenza vaccines
3. TransactRx Pharmacy Vaccine Billing Provider Partners with R.J. Hedges & Associates
4. Study offers new way to discover HIV vaccine targets
5. Parents Worries About HPV Vaccine on the Rise: Study
6. Japanese P2 study shows potential of combined vaccine and steroid drug in castration-resistant PCa
7. Japanese P2 study shows potential of combined vaccine and steroid drug in castration resistant PCa
8. Chicken pox vaccine saving childrens lives
9. Prediction of seasonal flu strains improves chances of universal vaccine
10. New cancer vaccine shows future promise in treating and preventing metastatic cancers
11. H1N1 Swine Flu Vaccine Tied to Sleep Disorder in British Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... OAK BROOK, Ill. (PRWEB) , ... December 07, 2016 , ... ... linked to early-stage brain damage, according to a study appearing online in the journal ... the incidence is expected to increase significantly due to the rapidly aging population. Damage ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... AUSTIN, TX (PRWEB) , ... OCTOBER XX, 2016 ... ... may help solve another mystery. A new study entitled “Canine Filamentous Dermatitis ... Morgellons disease can occur in dogs. The study was published in the prestigious ...
(Date:12/7/2016)... ... 07, 2016 , ... Texas Premier Locksmith , a ... by unethical locksmith companies and is urging Search Engines to improve verification methods ... Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked out of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... WellnessPro Plus for consumers and healthcare professionals to manage chronic and acute ... the treatment modalities available in a single device. The announcement is part ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Global Hospital Linen Supply and Management Services Market: ... supply and management services market presents a comprehensive analysis ... regional level. The study provides historic data of 2015 ... 2024 based on revenue (US$ Bn). The drivers and ... their impact on demand during the forecast period have ...
(Date:12/7/2016)... Dec. 7, 2016  Palatin Technologies, Inc. ("Palatin") ... on a previously disclosed underwritten public offering of ... acted as sole book-running manager, Roth Capital Partners ... acted as co-manager for the offering. ... in net proceeds, allowing us to continue advancing ...
(Date:12/7/2016)... 2016  Northwest Biotherapeutics (Nasdaq: NWBO ... company developing DCVax® personalized immune therapies for solid ... has not accepted the Company,s plan of remediation ... and the Company has notified Nasdaq of its ... from listing on Nasdaq.  Upon withdrawal from Nasdaq, ...
Breaking Medicine Technology: